Publication: Reactivation of latent HIV-1 in central memory CD4+ T cells through TLR-1/2 stimulation
Open/View Files
Date
2013
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
BioMed Central
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Novis, Camille L, Nancie M Archin, Maria J Buzon, Eric Verdin, June L Round, Mathias Lichterfeld, David M Margolis, Vicente Planelles, and Alberto Bosque. 2013. “Reactivation of latent HIV-1 in central memory CD4+ T cells through TLR-1/2 stimulation.” Retrovirology 10 (1): 119. doi:10.1186/1742-4690-10-119. http://dx.doi.org/10.1186/1742-4690-10-119.
Research Data
Abstract
Background: Toll-like receptors (TLRs) are crucial for recognition of pathogen-associated molecular patterns by cells of the innate immune system. TLRs are present and functional in CD4+ T cells. Memory CD4+ T cells, predominantly central memory cells (TCM), constitute the main reservoir of latent HIV-1. However, how TLR ligands affect the quiescence of latent HIV within central memory CD4+ T cells has not been studied. Results: We evaluated the ability of a broad panel of TLR agonists to reactivate latent HIV-1. The TLR-1/2 agonist Pam3CSK4 leads to viral reactivation of quiescent HIV in a model of latency based on cultured TCM and in resting CD4+ T cells isolated from aviremic patients. In addition, we investigated the signaling pathway associated with Pam3CSK4 involved in HIV-1 reactivation. We show that the transcription factors NFκB, NFAT and AP-1 cooperate to induce viral reactivation downstream of TLR-1/2 stimulation. Furthermore, increasing levels of cyclin T1 is not required for TLR-mediated viral reactivation, but induction of viral expression requires activated pTEFb. Finally, Pam3CSK4 reactivates latent HIV-1 in the absence of T cell activation or proliferation, in contrast to antigen stimulation. Conclusions: Our findings suggest that the signaling through TLR-1/2 pathway via Pam3CSK4 or other reagents should be explored as an anti-latency strategy either alone or in combination with other anti-latency drugs.
Description
Other Available Sources
Keywords
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service